{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T21:00:36Z","timestamp":1765486836269,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>COVID-19 vaccination has been associated with rare but severe complications characterized by thrombosis and thrombocytopenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results<\/jats:title><jats:p>Here we present three patients who developed <jats:italic>de novo<\/jats:italic> or relapse atypical hemolytic uremic syndrome (aHUS) in native kidneys, a median of 3 days (range 2-15) after mRNA-based (Pfizer\/BioNTech\u2019s, BNT162b2) or adenoviral (AstraZeneca, ChAdOx1 nCoV-19) COVID-19 vaccination. All three patients presented with evident hematological signs of TMA and AKI, and other aHUS triggering or explanatory events were absent. After eculizumab treatment, kidney function fully recovered in 2\/3 patients. In addition, we describe two patients with dubious aHUS relapse after COVID-19 vaccination. To assess the risks of vaccination, we retrospectively evaluated 29 aHUS patients (n=8 with native kidneys) without complement-inhibitory treatment, who received a total of 73 COVID-19 vaccinations. None developed aHUS relapse after vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, aHUS should be included in the differential diagnosis of patients with vaccine-induced thrombocytopenia, especially if co-occuring with mechanical hemolytic anemia (MAHA) and acute kidney injury (AKI). Still, the overall risk is limited and we clearly advise continuation of COVID-19 vaccination in patients with a previous episode of aHUS, yet conditional upon clear patient instruction on how to recognize symptoms of recurrence. At last, we suggest monitoring serum creatinine (sCr), proteinuria, MAHA parameters, and blood pressure days after vaccination.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1056153","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:16:07Z","timestamp":1669976167000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["COVID-19 vaccination and Atypical hemolytic uremic syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Romy N.","family":"Bouwmeester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther M.G.","family":"Bormans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Duineveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjan D.","family":"van Zuilen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Els","family":"van de Logt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack F.M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole C.A.J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"B1","article-title":"A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome","volume":"70","author":"Westra","year":"2012","journal-title":"Neth J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: A prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-012-2131-y","article-title":"Atypical hemolytic uremic syndrome in children: Complement mutations and clinical characteristics","volume":"27","author":"Geerdink","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"B8","article-title":"Hepatitis b vaccine-associated atypical hemolytic uremic syndrome","volume":"30","author":"Avc\u0131","year":"2013","journal-title":"Turk J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-018-4091-3","article-title":"Eculizumab in atypical hemolytic uremic syndrome: Strategies toward restrictive use","volume":"34","author":"Wijnsma","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910791","article-title":"Coagulopathies after vaccination against SARS-CoV-2 may be derived from a combined effect of SARS-CoV-2 spike protein and adenovirus vector-triggered signaling pathways","volume":"22","author":"Kircheis","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"117607","DOI":"10.1016\/j.jns.2021.117607","article-title":"Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review","volume":"428","author":"Sharifian-Dorche","year":"2021","journal-title":"J Neurol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.791429","article-title":"Complement mediated hemolytic anemias in the COVID-19 era: Case series and review of the literature","volume":"12","author":"Fattizzo","year":"2021","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2022030258","article-title":"A population-based analysis of the risk of glomerular disease relapse after COVID-19 vaccination","volume":"33","author":"Canney","year":"2022","journal-title":"JASN"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.07.004","article-title":"Atypical hemolytic and uremic syndrome triggered by infection with SARS-CoV2","volume":"6","author":"Kaufeld","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.030","article-title":"Atypical HUS relapse triggered by COVID-19","volume":"99","author":"Ville","year":"2021","journal-title":"Kidney Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012752","article-title":"COVID-19 as a potential trigger of complement-mediated atypical HUS","volume":"138","author":"El Sissy","year":"2021","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1001366","article-title":"Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report","volume":"13","author":"Rysava","year":"2022","journal-title":"Front Immunol"},{"key":"B20","first-page":"6","article-title":"Recurrence of atypical hemolytic uremic syndrome after COVID-19 vaccination","volume":"9","author":"Dos Santos","year":"2022","journal-title":"Can J Kidney Health Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.07.012","article-title":"Atypical hemolytic uremic syndrome occurring after receipt of mRNA-1273 COVID-19 vaccine booster: A case report","author":"Claes","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddg363","article-title":"Complement factor h mutations and gene polymorphisms in haemolytic uraemic syndrome: the c-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease","volume":"12","author":"Caprioli","year":"2003","journal-title":"Hum Mol Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi066","article-title":"Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32","volume":"14","author":"Esparza-Gordillo","year":"2005","journal-title":"Hum Mol Genet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor h autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1159\/000519461","article-title":"Atypical hemolytic uremic syndrome after ChAdOx1 nCoV-19 vaccination in a patient with homozygous CFHR3\/CFHR1 gene deletion","volume":"146","author":"Ferrer","year":"2022","journal-title":"Nephron"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1254743\/v1","article-title":"Hemolytic uremic syndrome: A covid-19 vaccine reaction case report","author":"Aku","year":"2022","journal-title":"Research Square"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1007\/s11739-021-02778-w","article-title":"Immune thrombocytopenia following COVID-19 mRNA vaccine: Casuality or causality","volume":"17","author":"Pasin","year":"2022","journal-title":"Intern Emerg Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/mbc.0000000000001082","article-title":"ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: Three cases of immune thrombocytopenia after 107\u200a720 doses of ChAdOx1 vaccination in Thailand","volume":"33","author":"Uaprasert","year":"2022","journal-title":"Blood Coagul Fibrinol"},{"key":"B31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12882-021-02616-3","article-title":"First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine - case report","volume":"22","author":"Osmanodja","year":"2021","journal-title":"BMC Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015545","article-title":"SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura","volume":"139","author":"Shah","year":"2022","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008248","article-title":"Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor d inhibition","volume":"136","author":"Yu","year":"2020","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.05.006","article-title":"Complement activation in patients with COVID-19: A novel therapeutic target","volume":"146","author":"Cugno","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.260117","article-title":"Complement C5 inhibition in patients with COVID-19 - a promising target","volume":"105","author":"Regis Peffault De","year":"2020","journal-title":"Haematologica"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","article-title":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases","volume":"220","author":"Magro","year":"2020","journal-title":"Transl Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.742446","article-title":"Complement alternative and mannose-binding lectin pathway activation is associated with COVID-19 mortality","volume":"12","author":"Defendi","year":"2021","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.74974","article-title":"Vaccine-induced COVID-19 mimicry syndrome","volume":"11","author":"Kowarz","year":"2022","journal-title":"eLife"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279155","article-title":"Complement dysregulation is associated with severe COVID-19 illness","volume":"107","author":"Yu","year":"2021","journal-title":"Haematologica"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-021-01677-8","article-title":"SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies","volume":"49","author":"Almehdi","year":"2021","journal-title":"Infection"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1056153\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:16:13Z","timestamp":1669976173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1056153\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2022.1056153"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1056153","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"article-number":"1056153"}}